Hong‐Hu Zhu

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

Hong‐Hu Zhu, Xiaohui Zhang, Ya‐Zhen Qin et al. · Blood · 2013 · 324 citations · Full text

Medicine, Oncology, Outcomes Research +7

Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial

Hong‐Hu Zhu, Depei Wu, Jie Jin et al. · Journal of Clinical Oncology · 2013 · 181 citations

Medicine, Hematology, Pharmacology +15

Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial

Hong‐Hu Zhu, Depei Wu, Xin Du et al. · The Lancet Oncology · 2018 · 146 citations

Medicine, Hematology, Oncology +8

In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification

Yu Wang, Depei Wu, Qifa Liu et al. · Blood · 2014 · 130 citations

Medicine, Molecular Medicine, Oncology +11

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission

Xiao‐Jun Huang, Hong‐Hu Zhu, Ying‐Jun Chang et al. · Blood · 2012 · 122 citations · Full text

Medicine, Hematology, Oncology +17